Effects of Recombinant Agouti-Signaling Protein on Melanocortin Action
Ying-Kui Yang,
Michael M. Ollmann,
Brent D. Wilson,
Chris Dickinson,
Tadataka Yamada,
Gregory S. Barsh and
Ira Gantz
Departments of Internal Medicine (Y-K.Y., T.Y.), Pediatrics (C.D.),
Physiology (T.Y.), and Surgery (I.G.) University of Michigan
Ann Arbor, Michigan 48109-0682
Howard Hughes Medical
Institute and The Departments of Pediatrics and Genetics Stanford
University (M.M.O., B.D.W., G.S.B.) Stanford, California
94305-5428
 |
ABSTRACT
|
---|
Mouse agouti protein is a paracrine signaling
molecule that has previously been demonstrated to be an antagonist of
melanocortin action at several cloned rodent and human melanocortin
receptors. In this study we report the effects of agouti-signaling
protein (ASIP), the human homolog of mouse agouti, on the action of
-MSH or ACTH at the five known human melanocortin receptor subtypes
(hMCR 15). When stably expressed in L cells (hMC1R, hMC3R, hMC4R,
hMC5R) or in the adrenocortical cell line OS3 (hMC1R, hMC2R, hMC4R),
purified recombinant ASIP inhibits the generation of cAMP stimulated by
-MSH (hMC1R, hMC3R, hMC4R, hMC5R) or by ACTH (hMC2R). However,
dose-response and Schild analysis indicated that the degree of ASIP
inhibition varied significantly among the receptor subtypes; ASIP is a
potent inhibitor of the hMC1R, hMC2R, and hMC4R, but has relatively
weak effects at the hMC3R and hMC5R. These analyses also indicated that
the apparent mechanism of ASIP antagonism varied among receptor
subtypes, with characteristics consistent with competitive antagonism
observed only at the hMC1R, and more complex behavior observed at the
other receptors. ASIP inhibition at these latter receptors,
nonetheless, can be classified as surmountable (hMC3R, hMC4R and hMC5R)
or nonsurmountable (hMC2R). Recombinant ASIP also inhibited binding of
radiolabeled melanocortins,
[125I-Nle4,
D-Phe7]
-MSH and
[125I-Phe2,
Nle4]ACTH 124, to the hMCR 15 receptors,
with a relative efficacy that paralleled the ability of ASIP to inhibit
cAMP accumulation at the hMC1R, hMC2R, hMC3R, and hMC4R. These results
provide new insight into the biochemical mechanism of ASIP action and
suggest that ASIP may play an important role in modulating melanocortin
signaling in humans.
 |
INTRODUCTION
|
---|
The human homolog of the mouse agouti gene encodes an
132-amino acid paracrine factor named agouti-signaling protein (ASIP).
Expression of the mRNA for this protein has been observed in diverse
human tissues including heart, liver, kidney, testis, ovary, adipose
tissue, and foreskin (1, 2). Although there is no firmly established
physiological function for this protein in humans, its role in
determination of coat color in fur-bearing mammals is well recognized
(3). Expression of agouti causes melanocytes to switch from the
synthesis of black or brown pigment, eumelanin, to the synthesis of
yellow pigment, pheomelanin, and normally controls the distribution of
these pigment types in individual hairs and in different regions of the
body (4).
The effects of agouti on fur color require the presence of a functional
melanocortin 1 receptor (MC1R), a G protein-coupled receptor in which
activating or loss-of-function mutations result in constitutive
synthesis of eumelanin or pheomelanin, respectively. The MC1R can be
activated by several peptide hormones derived from POMC, including
-MSH and ACTH. These peptides are produced at very high levels in
the brain and pituitary gland, but the role of melanocortins in the
normal control of pigmentation is uncertain. By contrast, activation of
the adrenal-specific MC2R by circulating ACTH is the major stimulus for
cortisol production, and activation of the MC3R and MC4R in the central
nervous system is thought to account for effects of melanocortins on
learning, behavior, and cardiovascular regulation.
Insight into the mechanism by which agouti exerts its control over coat
color has come from studies of Lu et al. (5), in which
recombinant mouse agouti protein was shown to antagonize the effects of
-MSH on heterologous cells that expressed the melanocortin-1
receptor (MC1R). Lu et al. found that mouse agouti protein
had no effect on the MC3R or MC5R but was a potent antagonist of the
MC4R, a brain-specific receptor that responds to ACTH as well as to
-MSH (6). Additional studies by Blanchard et al. (7) have
suggested that mouse agouti protein is a competitive antagonist of the
endogenous MC1R expressed on B16F10 mouse melanoma cells.
Potential pathophysiological action of agouti protein at one or more of
the extrapigmentary melanocortin receptors has been suggested by the
phenotype of mutant mice in which agouti is expressed ubiquitously,
such as viable yellow (Avy) or lethal yellow
(Ay), which have pleiotropic effects including
obesity, diabetes, and increased tumor susceptibility (8, 9, 10). These
findings have generated additional interest in the possible role of
agouti, melanocortins, and their receptors in weight homeostasis, but
the relevance of ASIP in human physiological or pathophysiogical
function remains to be elucidated. Here we report the biochemical
properties of ASIP relative to the full spectrum of human melanocortin
receptors including the adrenal-specific MC2R. Our findings indicate
that ASIP is a potent inhibitor of MC1R, MC2R, and MC4R signaling, but
that its mechanism of action is complex and unlikely to be explained by
simple competitive antagonism.
 |
RESULTS
|
---|
The preparations of agouti-signaling protein (ASIP) used in these
studies were purified from the conditioned media of insect cells
infected with a baculovirus construct that expressed recombinant ASIP
(M. M. Ollmann and G. S. Barsh, unpublished). Identical results were
obtained with several preparations that ranged in purity from
90%
to >99%. Cell lines that stably expressed each of the human
melanocortin receptor subtypes, hMCR 15, were exposed to various
concentrations of ASIP for 30 min before the addition of melanocortin
agonist, and cAMP accumulation was then measured after an additional 30
min incubation. Control experiments indicated that ASIP had no effect
on basal cAMP levels in cell lines transfected with the MCRs and also
had no effect on histamine-stimulated cAMP levels in L cells that
stably express the histamine H2 receptor (data not shown). As shown in
Fig. 1
, ASIP is an antagonist of melanocortin action at
all the human MCRs, but the extent of this inhibition is variable.
Furthermore, the apparent mechanism of ASIP inhibition at the various
receptor subtypes is also different.

View larger version (37K):
[in this window]
[in a new window]
|
Figure 1. Inhibition of Melanocortin Peptide Action on Cloned
Human Melanocortin Receptors hMC1R (panel A); hMC2R (panel B); hMC3R
(panel C); hMC4R (panel D); hMC5R (panel E). hMCR1, 3, 4 and 5 are
Stably Expressed in L Cells. hMC2R is Stably Expressed in OS3 Cells
The panels depict dose-response curves for the melanocortin agonist in
the presence of increasing concentration of ASIP (n = 3 for hMCR
1, 3, 4, 5, n = 4 for hMC2R). Insets depict the
Schild regression plots. The amount of receptor protein was determined
as described in Materials and Methods and is 521 fmol/mg
protein (hMC1R), 500 fmol/mg protein (hMC2R), 592 fmol/mg protein
(hMC3R), 480 fmol/mg protein (hMC4R), and 524 fmol/mg protein
(hMC5R).
|
|
In L cells that express the hMC1R, ASIP induces a parallel rightward
shift in the dose-response curves for
-MSH-stimulated cAMP
generation and has no significant effect on maximal stimulation (Fig. 1A
). To gain additional insight into the mechanism of ASIP action, we
plotted the EC50 of
-MSH (dose ratio) as a function of
antagonist concentration (inset, Fig. 1A
). For a competitive
antagonist, the agonist dose ratio is proportionate to the change in
antagonist concentration, and the slope of this plot should approximate
unity (Schild analysis). Our results with the hMC1R are consistent with
competitive antagonism, since the slope of the Schild regression is
0.81 ± 0.19 (Fig. 1A
), with an inhibitory constant
(Ki) of 0.47 ± 0.06 nM (Table 1
). Similar results were obtained when we expressed the
hMC1R in an adrenocortical cell line, OS3 (see below), with a Schild
regression slope of 0.84 ± 0.24 and a Ki of 0.53
± 0.05 nM (Fig. 2A
and Table 1
).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 2. Inhibition of hMC1R and hMC4R Stably Expressed in
OS3 Cells by Recombinant Human Agouti-Signaling Protein (ASIP) (n
= 3)
|
|
The action of agouti or ASIP at the mouse or human MC2R has not been
reported previously, in part due to difficulties that we and others
have encountered in generating heterologous cell lines that
functionally express significant levels of this receptor. To surmount
these problems, we made use of OS3 cells, a receptor-deficient
derivative of the adrenocortical carcinoma cell line Y1 (11). OS3 cells
stably transfected with the hMC2R exhibit nearly a 100-fold increase in
cAMP accumulation after stimulation by ACTH (Fig. 1B
), in contrast to
hMC2R-transfected L cells or 293 cells, in which there is no response
to ACTH (data not shown). The magnitude of this response is especially
striking compared with other MCRs expressed in L cells, which generally
exhibit a maximal level of ligand-stimulated cAMP accumulation less
than 10-fold (Fig. 1
), and is not due to differences in levels of
receptor expression, because similar results were observed using hMC2R
expressed in two different vectors (data not shown), and competitive
binding assays indicated similar levels of expression for all five
receptor subtypes (see legend to Fig. 1
).
When OS3 cells that expressed the hMC2R were exposed to different
concentrations of ACTH and ASIP, we observed an unexpected pattern of
antagonism (Fig. 1B
). Similar to its effects at the hMC1R, ASIP is a
potent antagonist of the hMC2R; however, the pattern of dose-response
inhibition is very different in that the maximum stimulatory responses
elicited by ACTH are markedly diminished and plateau well below the
levels attained in the absence of ASIP. This characteristic is a
hallmark of noncompetitive antagonism, but the effects we observed are
not completely consistent with the textbook definition of
noncompetitive antagonism because the EC50 values for cAMP
generation at different ASIP concentrations do not remain constant. In
the discussion that follows, we describe the effects of ASIP on the
hMC2R as nonsurmountable antagonism.
The effects of ASIP on the hMC3R, hMC4R, and hMC5R were examined in L
cells (Fig. 1
, C-E); for the hMC4R, the effects of ASIP were also
examined in OS3 cells (Fig. 2B
). At all three receptors, the effects of
ASIP are surmountable at high agonist concentrations, similar to the
pattern observed at the hMC1R (Fig. 1A
, C-E). The Schild regression
slopes for the hMC3R, hMC4R, and hMC5R are significantly less than
unity; therefore, the empirical Ki values for these
receptors can only be used as an estimate of the dissociation constant
(Table 1
). Nonetheless, comparison of Ki values suggest a relative
order of sensitivity to ASIP antagonism of MC4R > hMC1R >
hMC5R > hMC3R (Table
I). Analysis of the hMC4R expressed in OS3
cells gave nearly identical results to those obtained in L cells, with
Schild regression slopes of 0.73 ± 0.01 and 0.71 ± 0.1 and
Ki values of 0.16 ± 0.03 nM and 0.14
± 0.02 nM, respectively (Fig. 2B
and Table 1
).
To investigate whether the effects of ASIP on cAMP generation could be
explained by effects on melanocortin binding, we used the radiolabeled
melanocortin agonist [I125-Nle4,
D-Phe7]
-MSH (NDP-MSH) (12) to study the
hMC1R, hMC3R, hMC4R, and hMC5R (Fig. 3A
). With the
exception of the hMC5R, the ability of ASIP to inhibit
I125-NDP-MSH to these receptors parallels the ability of
ASIP to inhibit cAMP generation, with MC4R
hMC1R >
hMC3R > hMC5R. I125-NDP-MSH did not bind to the hMC2R
(data not shown), and therefore we used
[I125-Phe2, Nle7]ACTH124 (Fig. 3B
). The effects of ASIP on binding of this melanocortin to the hMC2R
are approximately equivalent to that seen at the hMC1R and hMC4R and
indicate that while ASIP interacts specifically with all human MCRs, it
is a potent antagonist of the hMC1R, hMC2R, and hMC4R, and a relatively
weak antagonist of the hMC3R and hMC5R.

View larger version (15K):
[in this window]
[in a new window]
|
Figure 3. Competition Binding Studies Demonstrating the
Effect of ASIP on Binding of (A) 125I-Labeled NDP-MSH to
hMCR 1, 3, 4, and 5 (n = 3) and (B)
[125I-Phe2, Nle4 ]ACTH 124
Binding to hMC2R (n = 3)
|
|
 |
DISCUSSION
|
---|
The human ASIP gene was isolated based on its sequence similarity
to the mouse agouti gene, but its role in human skin color,
hair color, or regulation of body weight has been uncertain. Our
results demonstrate that melanocortin signaling and binding to the
hMC1R, hMC2R, and hMC4R are inhibited by nanomolar levels of ASIP and
therefore suggest that variation in ASIP expression could affect the
physiological endpoints controlled by these receptors in melanocytes,
the adrenal gland, or the central nervous system, respectively. Low
levels of ASIP expression detectable by RT-PCR have been reported in
several tissues including skin and adipocytes, but expression has not
been detected in the adrenal gland or the brain.
Our conclusions regarding ASIP action at the hMC1R and hMC4R are
consistent with previous analyses of the mouse agouti protein (5, 7).
However, we found that ASIP could antagonize melanocortin signaling at
the hMC3R and hMC5R, which differs from the results of Lu et
al. (5), who found that mouse agouti protein had no effect on the
rat MC3R or the mouse MC5R. These differences are unlikely to be
explained by variation between the sequences for mouse agouti and ASIP
or by impurities in the preparations used, because we have observed
similar results with a preparation of mouse agouti protein that is
99% pure (data not shown). Instead, the absence of rat MC3R
inhibition by mouse agouti protein, as reported by Lu et al.
(5), may reflect a quantitative rather than qualitative difference from
our observations with the hMC3R, because we observed significant
inhibition of the hMC3R only at ASIP or mouse agouti
concentrations
10-7 M. With the mouse
MC5R, however, Lu et al. (5) found no inhibition of
10-7 M agouti protein; therefore, our
observations that the hMC5R is sensitive to relatively low
concentrations of ASIP or mouse agouti may reflect differences between
the MC5R of rodents and humans.
In examining the effects of ASIP on the MC2R we made the surprising
observation that the ACTH response of OS3 cells transfected with the
hMC2R is extremely robust, with a nearly 100-fold increase in levels of
cAMP accumulation. Expression of a functional MC2R has not been
possible in L cells or 293 cells, but recently, Cammas et
al. (13) reported that a functional mouse MC2R could be expressed
in HeLa cells. The basis of the difference between OS3 cells or HeLa
cells and other cell types is not known, but is likely to involve both
receptor-specific and cell-specific components, because several
attempts at expressing the hMC1R and hMC4R receptor in OS3 cells gave
results similar to those observed when these receptors were expressed
in L cells, with no more than a 6-fold increase in levels of cAMP
accumulation.
The nonsurmountable nature of the hMC2R response to ASIP inhibition in
OS3 cells is also surprising. This characteristic is receptor-specific
and not cell-specific, since the effects of ASIP on the hMC1R or the
hMC4R were nearly identical in L cells compared with OS3 cells. At the
hMC3R, hMC4R, and hMC5R,
-MSH can surmount the effects of ASIP, but
inhibition of these receptors is not consistent with competitive
antagonism, since changes in the EC50 of
-MSH (dose
ratio) are not proportionate to changes in ASIP concentration. In fact,
it is only the hMC1R at which the effects of ASIP conform to those
predicted for a competitive antagonist; in this regard, our findings
are consistent with those studies by Blanchard et al. (7) of
the endogenous MC1R of mouse B16F10 melanoma cells (7). Nonetheless,
our conclusions, and those of others, are not based on direct
measurement of ASIP binding, and further studies that utilize a
radiolabeled or tagged form of ASIP may help determine whether or not
the molecular nature of ASIP action exhibits fundamental differences
among melanocortin receptor subtypes.
Our data underscore the potential for ASIP or a closely related
molecule to act as a physiological or pathophysiological antagonist of
the hMC1R, hMC2R, or hMC4R. By analogy to the phenotypes displayed by
mice that carry various agouti alleles, three hypotheses might be
considered. First, inhibition of MC1R signaling in mice produces a
switch from eumelanin to phaeomelanin, a cysteine-rich yellow pigment.
Very high levels of phaeomelanin are found in bright red human hair,
and it is possible that dominant inheritance of this phenotype through
pedigrees represents normal action of ASIP in humans. If so, ASIP
structure and/or expression is likely to be highly polymorphic in
humans, a hypothesis that is easily testable. Second, if ASIP or a
closely related molecule normally functions to inhibit hMC2R
activation, loss-of-function mutations might result in adrenocortical
hyperplasia with hypercortisolism and secondary suppression of ACTH
production, while gain-of-function mutations would produce a relative
deficiency of corticosteroids and increased serum ACTH levels. Closer
study of ASIP expression in normal and abnormal adrenal samples may
shed light on this possibility. Finally, the pleiotropic effects
observed in rodents with ectopic expression of agouti protein (obesity,
diabetes, predisposition to tumorigenesis) suggests that somatic or
germline mutations leading to ectopic ASIP expression in humans would
have pleiotropic effects similar to those observed in mice.
 |
MATERIALS AND METHODS
|
---|
Receptor Expression
The coding regions of the genes for the human melanocortin
receptors (hMCR) 15 were subcloned into the eukaryotic expression
vectors CMVneo (14) or in pBK-CMV (Stratagene; La Jolla, CA) according
to methods previously described (15). The genes encoding hMCR 1, 2, 3,
and 4 were previously cloned in our laboratory (6, 16) and that
encoding hMC5R was generated by PCR based on the sequence published by
Dr. Vijay Chhajlani (17). For these experiments, the receptor
constructs were stably expressed in L cells (fibroblast lineage) or in
OS3 cells (adrenal cortical lineage). Wild type OS3 cells and OS3 cells
stably expressing hMC2R in the eukaryotic expression vector pcDNA I
were a gift of Dr. Bernard P. Schimmer (University of Toronto, Toronto,
Canada). The hMC2R pcDNA I plasmid construct originated in the
laboratory of Dr. Roger Cone (Vollum Institute, Portland, OR). OS3
cells expressing both the hMC2R pcDNA I and hMC2R CMVneo constructs
were used in our studies. Transfection of cells was accomplished using
calcium phosphate coprecipitation (18), and permanently transfected
clonal cell lines were selected by resistance to the neomycin analog
G418. Untransfected L cells and OS3 cells exhibit no response to
melanocortin stimulation, and therefore there is no significant
background. The results depicted in each panel of Figs. 1
and 2
have
been obtained from single clones; qualitatively similar results have
been obtained with independent clones in replicate experiments.
Receptor number determined by competitive binding assay with the
Graphpad Prism program (Graphpad Software, San Diego, CA) was found to
be similar for the different cell lines depicted in Fig. 1
and is given
in the figure legend.
cAMP Assays
For our studies, we measured intracellular cAMP using an assay kit
(TRK 432, Amersham, Arlington Heights, IL). Cells transfected with the
coding regions of the human melanocortin receptor genes were grown to
confluence in 12-well (2.4 x 1.7 cm) tissue culture plates. L
cells were maintained in DMEM ( Life Technologies; Gaithersburg, MD)
containing 4.5 g/100 ml glucose, 10% fetal calf serum, 1
mM sodium pyruvate. OS3 cells were grown on Hams F-10
nutrient mixture containing L-glutamine (Life
Technologies). Media for both cell lines contained 100 U/ml penicillin
and streptomycin and, in the case of transfected cells, 1 mg/ml of
geneticin (G418). For assays, the media was removed and cells were
washed twice with Earles balanced salt solution (EBSS, Life
Technologies) containing 10 mM HEPES (pH 7.4), 1
mM glutamine, 26.5 mM sodium bicarbonate, and 1
mg/ml BSA. Cells were preincubated for 30 min with human recombinant
ASIP in 0.5 ml EBSS before the addition of melanocortin agonist and 5
µl of 2 x 10-2 M
isobutylmethylxanthine. Cells were then incubated for another 30 min at
37 C at which time the reaction was stopped by adding ice-cold 100%
ethanol (500 µl/well). The cells in each well were scraped and
transferred to a 1.5-ml Eppendorf tube and centrifuged for 10 min at
1900 x g. The supernatant was evaporated in a 55 C
water bath with prepurified nitrogen gas. cAMP content was measured by
competitive binding assay according to the assay instructions. Human
ACTH (139),
-MSH, [Phe2, Nle7]ACTH
(124), and [Nle4,
D-Phe7]
-MSH were obtained from Peninsula
Laboratories, Inc. (Belmont, CA). Recombinant mouse agouti protein and
human ASIP were prepared according to the method of Ollmann et
al. (unpublished results). Each experiment was performed a minimum
of three times with duplicate wells. The mean value of the
dose-response data was fit to a sigmoid curve with a variable slope
factor using the nonlinear squares regression in Graphpad Prism
(Graphpad Software). Values determined from these fits were used for
calculating the Schild analysis linear regression plot. pA2
values were derived from the y = 0 intercept of the Schild plot of
the log of dose ratio minus one (log DR - 1) as previously
described (20). Ki values (the negative log of the
pA2) presented in Table 1
were determined for relative
comparison of ASIP potency. Since the slopes of the linear regression
analysis of hMCR 3, 4, and 5 are not unity, by strict definition, true
Ki values cannot be determined.
Binding Assays
After removal of media the cells were washed twice with EBSS and
preincubated with ASIP in 0.5 ml MEM (Life Technologies) containing
0.2% BSA for 30 min before incubation with 106 cpm of
radioligand. [125-Nle4,
D-Phe7]
-MSH was prepared by the
chloramine-T method according to the protocol modified from Tatro and
Reichlin (21), and binding experiments were performed using conditions
previously described (15, 16). [I125-Phe2,
Nle7]ACTH(124) was prepared as described by Hofmann
et al. (22), and binding experiments using this radioligand
were performed using conditions described by Rainey et al.
(23). Binding reactions were terminated by removing the media and
washing the cells twice with MEM containing 0.2% BSA. The cells were
lysed with 1% Triton X-100, and the radioactivity in the lysate was
quantified in a model 1285 Tracor Analytic
-counter. Nonspecific
binding was determined by measuring the amount of
125I-labeled melanocortin remaining bound in the presence
of 10-5 M unlabeled melanocortin, and specific
binding was calculated by subtracting nonspecifically bound
radioactivity from total bound radioactivity.
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Richard R. Neubig for his assistance in data
analysis. We are very grateful to Dr. Bernard P. Schimmer for providing
us with access to, and information about, the OS3 cell line.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Ira Gantz, 6504 MSRBI, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0682.
This work was supported by a Veterans Administration Merit Review Award
(I.G.), funds from the University of Michigan Gastrointestinal Peptide
Research Center (NIH Grant P30DK-34933), and a grant from the NIH to
G.S.B. (DK-28506). M.M.O. and B.D.W. are supported by Graduate
(EY07106) and Medical Scientist Trainee (GM07365) grants. G.S.B. is an
Assistant Investigator of the Howard Hughes Medical Institute.
Received for publication May 15, 1996.
Revision received December 13, 1996.
Accepted for publication December 18, 1996.
 |
REFERENCES
|
---|
-
Kwon HY, Bultman SJ, Löffler C, Chen W-J, Furdon
PJ, Powell JG, Usala A-L, Wilkison W, Hansmann I, Woyhik RP 1994 Molecular structure and chromosomal mapping of the human homolog of the
agouti gene. Proc Natl Acad Sci USA 91:97609764[Abstract/Free Full Text]
-
Wilson BD, Ollmann MM, Kang L, Stoffel M, Bell GI, Barsh GS 1995 Structure and function of ASP, the human homolog of the
mouse agouti gene. Hum Mol Genet 4:223230[Abstract]
-
Silvers WK 1979 The Coat Colors of Mice. Springer-Verlag, New
York, pp 644
-
Vrieling H, Duhl DMJ, Millar SE, Miller KA, Barsh GS 1994 Differences in dorsal and ventral pigmentation result from regional
expression of the mouse agouti gene. Proc Natl Acad Sci USA 91:56675671[Abstract]
-
Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T,
Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD 1994 Agouti protein
is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371:799802[CrossRef][Medline]
-
Gantz I, Miwa H, Konda Y, Shimoto Y, Tashio T, Yamada T 1993 Molecular cloning, expression, and gene localization of a fourth
melanocortin receptor. J Biol Chem 268:1517415179[Abstract/Free Full Text]
-
Blanchard SG, Harris CO, Ittoop ORR, Nichols JS, Parks DJ
Truesdale AT, Wilkison WO 1995 Agouti antagonism of melanocortin
binding and action in the B16F10 murine
melanoma cell line. Biochemistry 34:1040610411[Medline]
-
Duhl DMJ, Vrieling H, Miller KA, Wolff GL, Barsh GS 1994 Neomorphic agouti mutations in obese yellow mice. Nat Genet 8:5965[Medline]
-
Michaud EJ, van Vugt MJ, Bultman SJ, Sweet HO, Davisson,
MT, Woychik RP 1994 Differential expression of a new dominant agouti
allele (Aiapy) is correlated with methylation state and is
influenced by parental lineage. Genes Dev 8:14631472[Abstract]
-
Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL 1994 Obesity,
diabetes, and neoplasia in yellow Avy/- mice: ectopic
expression of the agouti gene. FASEB J 8:479488[Abstract/Free Full Text]
-
Schimmer BP, Kwan WK, Tsao J, Qiu R 1995 Adrenocorticotropin-resistant mutants of the Y1 adrenal cell line fail
to express the adrenocorticotropin receptor. J Cell Physiol 163:164171[Medline]
-
Hadley ME, Anderson B, Heward CB, Sawyer TK, Hruby VJ 1981 Calcium-dependent prolonged effects on melanophores of [4-norleucine,
7-D-phenylalanine]-
-melanotropin. Science 213:10251027[Medline]
-
Cammas FM, Kapas S, Barker S, Clark AJ 1995 Cloning,
characterization and expression of a functional mouse ACTH receptor.
Biochem Biophys Res Commun 212:912918[CrossRef][Medline]
-
Brown NA, Steofko RE, Uhler MD 1990 Induction of alkaline
phosphatase in mouse L cells by overexpression of the catalytic subunit
of cAMP-dependent protein kinase. J Biol Chem 265:1318113189[Abstract/Free Full Text]
-
Gantz I, Schaffer M, DelValle J, Logsdon C, Campbell V, Uhler
M, Yamada T 1991 Molecular cloning of a gene encoding the histamine H2
receptor. Proc Natl Acad Sci USA 88:429433[Abstract]
-
Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G,
Watson S, DelValle J, Yamada T 1993 Molecular cloning of a novel
melanocortin receptor. J Biol Chem 268:82468250[Abstract/Free Full Text]
-
Chhajlani V, Muceniece R, Wikberg JES 1993 Molecular cloning
of a novel human melanocortin receptor. Biochem Biophys Res Commun 95:866873
-
Chen CA, Okayama H 1988 Calcium phosphate-mediated gene
transfer: a highly efficient transfection system for stably
transforming cells with plasmid DNA. Biotechniques 6:632638[Medline]
-
Deleted in proof
-
Sue R, Toomey ML, Todisco A, Soll AH, Yamada T 1985 Pirenzepine-sensitive muscarinic receptors regulate gastric
somatostatin and gastrin. Am J Physiol 248:G184G187
-
Tatro JB, Reichlin S 1987 Specific receptors for
alpha-melanocyte-stimulating hormone are widely distributed in tissues
of rodents. Endocrinology 121:19001907[Abstract]
-
Hofmann K, Romavacek H, Stehle CJ, Finn FM, Bothner-By AA,
Mishra PK 1986 Radioactive probes for adrenocorticotropic hormone
receptors. Biochemistry 25:13391346[Medline]
-
Rainey WE, Viard I, Saez JM 1989 Transforming growth factor
ß treatment decreases ACTH receptors on ovine adrenocortical cells.
J Biol Chem 264:2147421477[Abstract/Free Full Text]